|
1.
|
Paolone DR: Benign prostatic hyperplasia.
Clin Geriatr Med. 26:223–239. 2010. View Article : Google Scholar
|
|
2.
|
Roehrborn CG: Male lower urinary tract
symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin
North Am. 95:87–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Gat Y, Gornish M, Heiblum M and Joshua S:
Reversal of benign prostate hyperplasia by selective occlusion of
impaired venous drainage in the male reproductive system: novel
mechanism, new treatment. Androl. 40:273–281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Xie Q, Wang H, Lin F and Liao Y:
Abnormality of growth regulatory factors in benign prostatic
hyperplasia. Chin J Urol. 22:520–522. 2001.(In Chinese).
|
|
5.
|
Steiner MS: Review of peptide growth
factors in benign prostatic hyperplasia and urological malignancy.
J Urol. 153:1085–1096. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Li Y, Fang Y, Xu Youqi, Li Q, Deng X and
Jiang J: Role of the epidermal growth factor receptor in human
benign hyperplastic prostate tissue. J Clin Urol. 11:199–201.
1996.(In Chinese).
|
|
7.
|
Jia B, Tang Z, Li WM and Cai WQ: The
effects of epidermal growth factor on the expression of Bcl-2, Bax
and c-myc in mice prostate cells. Chin J Gerontol. 27:251–252.
2007.(In Chinese).
|
|
8.
|
Lin JM, Hong ZF, Zhou JH, Zhuang QC, Zhao
JY and Zhou HT: Expression of growth factor related to angiogenesis
on prostatic hyperplasia in rats. J Fujian Univ Tradit Chin Med.
18:63–66. 2008.(In Chinese).
|
|
9.
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Hong ZF: Candidate targets for research on
benign prostatic hyperplasia. Zhonghua Nan Ke Xue. 14:771–774.
2008.(In Chinese).
|
|
11.
|
Haura EB, Turkson J and Jove R: Mechanisms
of disease: Insights into the emerging role of signal transducers
and activators of transcription in cancer. Nat Clin Pract Oncol.
2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L,
Fernández-Luna JL, Nuñez G, Dalton WS and Jove R: Constitutive
activation of Stat3 signaling confers resistance to apoptosis in
human U266 myeloma cells. Immunity. 10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Karni R, Jove R and Levitzki A: Inhibition
of pp60c-Src reduces Bcl-XL expression and reverses the transformed
phenotype of cells overexpressing EGF and HER-2 receptors.
Oncogene. 18:4654–4662. 1999. View Article : Google Scholar
|
|
14.
|
Coqueret O and Gascan H: Functional
interaction of STAT3 transcription factor with the cell cycle
inhibitor p21WAF1/CIP1/SDI1. J Biol Chem. 275:18794–18800. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bienvenu F, Gascan H and Coqueret O:
Cyclin D1 represses STAT3 activation through a Cdk4-independent
mechanism. J Biol Chem. 276:16840–16847. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Roehrborn CG, Nuckolls JG, Wei JT and
Steers W; BPH Registry and Patient Survey Steering Committee: The
benign prostatic hyperplasia registry and patient survey: study
design, methods and patient baseline characteristics. BJU Inter.
100:813–819. 2007. View Article : Google Scholar
|
|
17.
|
Black L, Naslund MJ, Gilbert TD Jr, Davis
EA and Ollendorf DA: An examination of treatment patterns and costs
of care among patients with benign prostatic hyperplasia. Amer J
Manag Care. 12(4 Suppl): S99–S110. 2006.PubMed/NCBI
|
|
18.
|
MacDonald R and Wilt TJ: Alfuzosin for
treatment of lower urinary tract symptoms compatible with benign
prostatic hyperplasia: A systematic review of efficacy and adverse
effects. Urology. 66:780–788. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Roehrborn CG: Efficacy and safety of
once-daily alfuzosin in the treatment of lower urinary tract
symptoms and clinical benign prostatic hyperplasia: a randomized,
placebo-controlled trial. Urology. 58:953–959. 2001. View Article : Google Scholar
|
|
20.
|
Djavan B and Marberger M: A meta-analysis
on the efficacy and tolerability of α1-adrenoceptor antagonists in
patients with lower urinary tract symptoms suggestive of benign
prostatic obstruction. Eur Urol. 36:1–13. 1999.
|
|
21.
|
Gormley GJ, Stoner E, Bruskewitz RC,
Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J,
Bracken BR and Tenover JS: The effect of finasteride in men with
benign prostatic hyperplasia. The Finasteride Study Group. N Engl J
Med. 327:1185–1191. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Roehrborn C, Boyle P, Nickel JC, Hoefner K
and Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators:
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types
1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
Urology. 60:434–441. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Boyle P, Robertson C, Lowe F and Roehrborn
C: Meta-analysis of clinical trials of permixon in the treatment of
symptomatic benign prostatic hyperplasia. Urology. 55:533–539.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Wilt T, Ishani A, MacDonald R, Stark G,
Mulrow C and Lau J: Beta-sitosterols for benign prostatic
hyperplasia. Cochrane Database of Syst Rev. (2):
CD0010432000.PubMed/NCBI
|
|
25.
|
Wilt T, Ishani A, Mac Donald R, Rutks I
and Stark G: Pygeum africanum for benign prostatic
hyperplasia. Cochrane Database of Syst Rev. (1):
CD0010442002.PubMed/NCBI
|
|
26.
|
Zhou J, Lin J, Xu W, Zhong X, Xie J and
Hong Z: Effects of Qianliening capsule on the expression of IL-10
and TNF-α in benign prostatic hyperplasia. Chin Arch Tradit Chin
Med. 28:2657–2569. 2010.(In Chinese).
|
|
27.
|
Zhou JH, Hong ZF, Lin JM, Zhao JY and Zhou
HT: Effect of Qianliening granule on experimental hyperplasia of
prostate. J Fujian Univ Tradit Chin Med. 18:45–47. 2008.(In
Chinese).
|
|
28.
|
Zhou HT, Lin JM, Zhao JY, Zhou JH and Hong
ZF: Inhibition effects of qianliening granule on IL-1β and its mRNA
expression in model rats. J Fujian Univ Tradit Chin Med. 20:21–24.
2010.
|
|
29.
|
Zhou J, Lin J, Xu W, Zhong X, Zheng Y,
Hong Z and Peng J: Qianliening capsule treats benign prostatic
hyperplasia through regulating the expression of sex hormones,
estrogen receptor and androgen receptor. Afr J Pharm Pharmacol.
6:173–180. 2012. View Article : Google Scholar
|
|
30.
|
Zhong X, Lin J, Zhou J, Xu W, Hong Z and
Peng J: Qianliening capsule treats benign prostatic hyperplasia
(BPH) by down-regulating the expression of PCNA, CyclinD1 and CDK4.
Afr J Biotechnol. 11:7731–7737. 2012.
|
|
31.
|
National Advisory Committee for Laboratory
Animal Research. Guidelines on the Care and Use of Animals for
Scientific Purposes. 2004
|
|
32.
|
Zheng HY, Xu W, Lin JM, Li H, Zhou JH and
Hong ZF: Toxicological studies on qianliening capsule. J Zhejiang
Univ Tradit Chin Med. 35:63–65. 2011.(In Chinese).
|
|
33.
|
Ilio KY, Sensibar JA and Lee C: Effect of
TGF-beta 1, TGF-alpha, and EGF on cell proliferation and cell death
in rat ventral prostatic epithelial cells in culture. J Androl.
16:482–490. 1995.PubMed/NCBI
|
|
34.
|
Peng J, Chen Y, Lin J, Zhuang Q, Xu W,
Hong Z and Sferra TJ: Patrinia scabiosaefolia extract
suppresses proliferation and promotes apoptosis by inhibiting the
STAT3 pathway in human multiple myeloma cells. Mol Med Report.
4:313–318. 2011.
|
|
35.
|
Ball S, Li C, Li PK and Lin J: The small
molecule, LLL12, inhibits STAT3 phosphorylation and induces
apoptosis in medulloblastoma and glioblastoma cells. PLoS One.
6:e188202011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Masuda M, Suzui M, Yasumatu R, Nakashima
T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
